When were used data from the “Study of Health in Pomerania,” Germany, to assess the relation of fatty liver disease to self-reported health care utilization and costs at baseline and 5 years, in a general population cohort study of 4310 adults aged 20 to 79 years at baseline, subjects with NAFLD and increased serum ALT levels, after controlling for comorbid condition, had 26% higher overall health care costs [9]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.